Antidepresan Tedavinin Metabolik Etkileri

Özet

Amaç: Bu çalışmada anksiyete ve depresif belirtileri olan hastalarda vücut ölçümleri, glukoz-insülin mekanizması ve lipid profilinin araştırılması ve antidepresanların bu metabolik parametreler üzerine etkisinin araştırılması planlanmıştır

Abstract

Introduction: This study aimed to investigate body measurements, glucose-insulin metabolism, and lipid profile in patients with anxiety and depressive symptoms and also the effects of antidepressant drugs on these metabolic parameters. Methods: The study included 40 outpatients and 32 healthy controls. The patients received antidepressant treatment (sertraline, escitalopram, fluoxetine, and venlafaxine) for 8 weeks. Body measurements were performed, and lipid, fasting blood glucose, and insulin levels were measured before and after treatment in patients and once in healthy controls. Insulin resistance was evaluated using the homeostasis model assessment (HOMA) index.Results: Body mass index was higher in patients than in healthy controls, and there was no change in patients after treatment. In patients, high-density lipoprotein (HDL) cholesterol levels increased owing to the antidepressant treatment. Insulin level and HOMA index had a